← Back to screener

Akebia Therapeutics, Inc. AKBA

Rank #2477 · Nasdaq · $0.2B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
14.8
P/E
-3.6
P/B
36.24
ROE
-992.8%
Op. Margin
-23.8%
Debt Ratio
5160%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -3.6x, P/B 36.24x. Ranks in the top 92% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -992.8%. Ranks in the top 90% of the universe.

Safety ★☆☆☆☆
Poor

Debt ratio 5160%. Ranks in the top 99% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★☆☆☆
Weak

Revenue growth of 0.0% year over year. Ranks in the top 64% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2014$0.0B$-0.0B$-0.0B$-0.0B–-8
2015$0.0B$-0.0B$-0.0B$-0.1B–-12
2016–$-0.0B$-0.0B$-0.1B–-9
2017–$-0.1B$-0.1B$0.1B–223
2018$0.0B$-0.1B$-0.1B$0.1B-8889.9184
2019$0.2B$-0.1B$-0.1B$0.1B-42.3529
2020$0.2B$-0.2B$-0.1B$0.1B-85.8307
2021$0.3B$-0.3B$-0.3B$0.6B-85.562
2022$0.3B$-0.4B$-0.4B$0.4B-127.5114
2023$0.3B$-0.1B$-0.1B$0.1B-27.6474
2024$0.2B$-0.0B$-0.1B$0.0B-23.85206
2025$0.2B$-0.0B$-0.1B$0.0B-23.85160

← See the full screener